» Articles » PMID: 39035723

Precision Based Approach to Tailoring Radiotherapy in the Multidisciplinary Management of Pediatric Central Nervous System Tumors

Overview
Specialty Oncology
Date 2024 Jul 22
PMID 39035723
Authors
Affiliations
Soon will be listed here.
Abstract

Modern day survivorship from childhood malignancies is estimated to be over 80%. However, central nervous system tumors remain the leading cause of cancer mortality in children and is the most common solid tumor in this population. Improved survivorship is, in part, a result of improved multidisciplinary care, often with a combination of surgery, radiation therapy, and systemic therapy. With improved survival, long term effects of treatment and quality of life impacts have been recognized and pose a challenge to maximize the therapeutic ratio of treatment. It has been increasingly more apparent that precise risk stratification, such as with the inclusion of molecular classification, is instrumental in efforts to tailor radiotherapy for appropriate treatment, generally towards de-intensification for this vulnerable patient population. In addition, advances in radiotherapy techniques have allowed greater conformality and accuracy of treatment for those who do require radiotherapy for tumor control. Ongoing efforts to tailor radiotherapy, including de-escalation, omission, or intensification of radiotherapy, continue to improve as increasing insight into tumor heterogeneity is recognized, coupled with advances in precision medicine employing novel molecularly-targeted therapeutics.

Citing Articles

IDH-mutant gliomas in children and adolescents - from biology to clinical trials.

Evans L, Trinder S, Dodgshun A, Eisenstat D, Whittle J, Hansford J Front Oncol. 2025; 14:1515538.

PMID: 39876890 PMC: 11773619. DOI: 10.3389/fonc.2024.1515538.

References
1.
Kortmann R, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V . Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys. 2000; 46(2):269-79. DOI: 10.1016/s0360-3016(99)00369-7. View

2.
Patil N, Kelly M, Yeboa D, Buerki R, Cioffi G, Balaji S . Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. Neuro Oncol. 2020; 23(6):990-998. PMC: 8168816. DOI: 10.1093/neuonc/noaa295. View

3.
Diamandis P, Aldape K . World Health Organization 2016 Classification of Central Nervous System Tumors. Neurol Clin. 2018; 36(3):439-447. DOI: 10.1016/j.ncl.2018.04.003. View

4.
van Dijk I, Oldenburger F, Cardous-Ubbink M, Geenen M, Heinen R, de Kraker J . Evaluation of late adverse events in long-term wilms' tumor survivors. Int J Radiat Oncol Biol Phys. 2010; 78(2):370-8. DOI: 10.1016/j.ijrobp.2009.08.016. View

5.
Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A . Phase I study of vemurafenib in children with recurrent or progressive BRAF mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020; 11(21):1942-1952. PMC: 7260122. DOI: 10.18632/oncotarget.27600. View